title: Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.
abstract: Lipoprotein-associated phospholipase A(2 )(Lp-PLA(2)), a member of the phospholipase superfamily, circulates primarily bound to low-density lipoprotein and has been associated with cardiovascular disease risk in epidemiologic studies. However, it has not been established whether Lp-PLA(2) is a risk marker or a risk factor. Identification of individuals with elevated Lp-PLA(2) may improve risk assessment, and Lp-PLA(2) may also provide an additional target of therapy. Statin therapy has been shown to reduce Lp-PLA(2), and selective inhibitors of Lp-PLA(2) are under development. Additional research is needed to further determine the role of Lp-PLA(2) in atherogenesis and atherothrombotic events.
authors.affiliation: Section of Cardiology, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030, USA. vnambi@bcm.tmc.edu
authors.forename: Vijay
authors.initials: V
authors.lastname: Nambi
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D010741:Phospholipases A / Q000097:blood* / Q000187:drug effects; D054467:Phospholipases A2; D011379:Prognosis; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010741:Phospholipases A; D054467:Phospholipases A2; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase